ClinicalTrials.gov
Cure8 trial brief
Why This Matters
Enteral nutrition (Modulen IBD) is being evaluated as a non-drug induction and maintenance strategy in children with Crohn’s disease; patients and caregivers may be interested because EEN can affect remission, nutrition, and growth without steroids.
Who Should Pay Attention
Pediatric patients with Crohn’s disease, parents and caregivers, pediatric gastroenterologists, dietitians, and researchers studying nutritional therapies in IBD.
Study Snapshot
Story typeClinical Reference
Evidence typeClinical trial
Enrollment40 participants
Study statusNot_yet_recruiting
Source depthTrial registry record
What To Know
This is a trial registry entry (study not yet recruiting) rather than a published result. The primary outcome is clinical remission at week 6–8 measured by the Pediatric Crohn’s Disease Activity Index (PCDAI < 10) after EEN with Modulen.
Secondary assessments include nutritional status, growth, and laboratory markers over predefined time points up to 12 months. The study is observational (prospective cohort) with planned enrollment of 40 pediatric patients (<18 years) with mild-to-moderate active Crohn’s disease.
Patients with severe complicated disease or those unable to tolerate enteral nutrition are excluded. Because this is a registry record, it reports the study design, eligibility, and planned outcomes but does not provide results, so clinical impact is unknown until the study is completed and results are published.
Keep In Mind
This is a registered observational study (not yet recruiting) and does not report results. The record describes planned outcomes and follow-up; do not interpret this as evidence of effectiveness until peer-reviewed results are available.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorAssiut University
Trial IDNCT07821645
Study typeObservational
Enrollment40 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedSep 16, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Conventional vs Biologic Therapy in Pediatric IBD
Pediatric-onset IBD can behave differently than adult-onset disease. Comparing conventional versus biologic approaches in children may help clarify relative effectiveness, safety, and impacts on growth and steroid...
Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease
A new Phase 2 trial is testing afimkibart (RO7790121) for moderate-to-severe Crohn's disease; people with Crohn's disease who have failed prior treatments may be especially interested in emerging therapies.
Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease
This study examines a combination of ustekinumab plus low‑dose upadacitinib for patients with refractory Crohn’s disease — a group with limited options after failing anti‑TNF and single‑agent therapy. Results could...